drugset

drugset / Trial / NCT00190723

A Study of LY317615 in Patients With Brain Tumors

NCT00190723 ↗

Phase 2 Completed 120 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.

Timeline

Start: 2002-10
Primary completion: —
Completion: 2006-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	—	—

Indications